Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001209191-22-035687

Options or other derivatives

  • Director acquired 43,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Mahatme Sandesh Director 2022-06-07 Grant or award · Director Stock Option (right to buy) +43,000 43,000 D: show line 1 in the form
Loading xslF345X03/doc4.xml…